Open AccessCost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
Author(s) -
William V. Padula,
Richard A. Larson,
Stacie B. Dusetzina,
Jane F. Apperley,
Rüdiger Hehlmann,
Michele Baccarani,
Ekkehard Eigendorff,
François Guilhot,
François Guilhot,
FrançoisXavier Mahon,
Giovanni Martinelli,
Jiřı́ Mayer,
Martin C. Müller,
Dietger Niederwieser,
Susanne Saußele,
Charles A. Schiffer,
Richard T. Silver,
Bengt Simonsson,
Rena M. Conti
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/h6kv-p452
Subject(s) - imatinib , myeloid leukemia , tyrosine kinase inhibitor , tyrosine kinase , medicine , cancer research , pharmacology , receptor , cancer